Navigation Links
STAAR Surgical's Visian ICL Procedure Performed Live on NBC's Today show
Date:3/4/2008

MONROVIA, Calif., March 4 /PRNewswire-FirstCall/ -- STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, congratulates Dr. Brian Boxer Wachler on his live surgical procedure on NBC's Today Show this morning correcting NBCSports.com columnist Alan Abrahamson's vision with STAAR's Visian ICL lenses.

The Visian ICL is the only foldable, minimally invasive lens approved in the U.S. for the correction of myopia, or nearsightedness, in adults. It can be especially useful in patients such as Abrahamson, who had a high prescription requirement to correct his nearsighted vision. The Visian ICL is approved for myopic patients as low as -3.0 diopters and delivers exceptional clarity and quality of vision.

During the brief procedure, which commonly takes 15 to 20 minutes per eye, Dr. Boxer Wachler made a micro incision to allow positioning of the implant behind the iris and in front of the natural lens. Both eyes were corrected during the show and Abrahamson was asked about any pain during the procedure by Meredith Vieira, co-anchor of the Today Show, to which he responded, "I cannot feel a thing." Before the procedure Abrahamson was unable to see the largest letter on the standard vision chart. Post-operatively, he said he could see "crisply and cleanly." He showed significant improvement instantaneously.

The Today Show segments can be viewed at:

http://www.msnbc.msn.com/id/21134540/vp/23463382#23463382

The implantable Collamer lens has been successfully implanted in over 80,000 eyes worldwide. In an FDA clinical trial, over 99 percent of patients were satisfied with their implant. The Visian ICL has a track record of stable, consistently excellent clinical outcomes. Data from research shows that the Visian ICL has some advantages over refractive surgical procedures such as PRK and LASIK, and has a lower chance of inducing higher order aberrations compared to LASIK. To learn more about the Visian ICL or to locate a certified surgeon in your area you can go to STAAR's consumer website: http://www.staar.com/html/visian-icl.html

About the VISIAN ICL

Made of a highly biocompatible Collamer(R) material containing a small amount of collagen, the Visian ICL's unique lens design allows for a minimally invasive procedure and an aesthetically pleasing outcome, because the lens is placed behind the iris. Unlike laser vision procedures the Visian ICL corrects vision without permanently altering the structure of the eye and can be removed if needed.

Doctors familiar with the technology have noted the ICL's stability, the safety of the procedure, superior clinical outcomes and high patient satisfaction rate. The Visian ICL is a refractive phakic implant intended for placement in the posterior chamber of the eye. The approved models are indicated for the correction of myopia in adults with myopia ranging from -3.0 to less than or equal to -15.0 diopters, with astigmatism less than or equal to 2.5 diopters at the spectacle plane, and the reduction of myopia in adults with myopia ranging from greater than -15.0 to -20.0 diopters with astigmatism less than or equal to 2.5 diopters at the spectacle plane, in patients 21 to 45 years of age with anterior chamber depth (ACD) 3.00 mm or greater, and a stable refractive history within 0.5 diopters for one year prior to implantation.

About STAAR Surgical

STAAR is a leader in the development, manufacture and marketing of minimally invasive ophthalmic products employing proprietary technologies. STAAR's products are used by ophthalmic surgeons and include the Visian ICL, a tiny, flexible lens implanted to correct refractive errors, as well as innovative products designed to improve patient outcomes for cataracts and glaucoma. The ICL is approved by the FDA for use in treating myopia, has received CE Marking and is sold in more than 40 countries. More information is available at http://www.staar.com.

CONTACT: Investors

EVC Group

Douglas Sherk, 415-896-6820

Matthew Selinger, 415-896-6817

Media

EVC Group

Steve DiMattia, 646-277-8706

Christopher Gale, 646-201-5431


'/>"/>
SOURCE STAAR Surgical Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. STAAR Surgical Reports Operational Progress
2. STAAR Surgical Announces Third Quarter 2007 Earnings Release Date and Conference Call
3. STAAR Surgical to Purchase Canons Interest in Japanese Joint Venture
4. STAAR Surgical Reports Third Quarter Results
5. Barry G. Caldwell Named Chief Executive Officer of STAAR Surgical
6. STAAR Surgical to Present at the BMO Capital Markets Focus on Healthcare Conference
7. STAAR Surgical Completes $5M Debt Financing for Purchase of Japanese Joint Venture
8. STAAR Surgical to Present at the Tenth Annual Needham Growth Conference
9. STAAR Surgical Announces Fourth Quarter and Full Year 2007 Earnings Release Date and Conference Call
10. UK junior doctors gaining less experience of common procedures
11. New male sling procedure helps prostate cancer survivors who suffer from urinary incontinence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... One of Australia,s successful biotechnology ... a new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ... to list on the ASX. Noxopharm is a clinic-ready ... a Phase 1 clinical study later this year. ... the biggest problems facing cancer patients - the ability of cancers ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: